Spectrum Pharmaceuticals (SPPI) Tuesday provided a full-year revenue outlook which is currently below analysts' expectations. The current guidance reflects an anticipated change in ordering patterns of FUSILEV due to the recent stabilization of the folate analog market.
Full-year revenues are currently forecast in a range of $160 million to $180 million. Analysts, based on consensus, currently expect full-year revenues of $297.33 million.
Full-year FUSILEV sales is expected to range between $80 million and $90 million, with first-quarter sales in the order of $10 million to $15 million.
For comments and feedback: editorial@rttnews.com